Clinical trials: Genitourinary Disease
Infertility
Clinical Performance and Safety Investigation of ENDOmetrial Washing MEdical DEvice Forielle
This is a multicenter, prospective randomized controlled, interventional investigation to assess the safety and clinical performance of Forielle, a medical device for endometrial washing, in restoring favorable endometrial…
- Trial name
- ENDOMEDE (NCT03387059)
- Testing
- Forielle
- Where
- 7 sites in Italy
- Volunteers
- 9 people
- Sponsor
- Merck KGaA, Darmstadt, Germany
Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2
A Comparison Of Study Drug Blood Levels After One Dose Of GSK189075 In Subjects With Normal And Reduced Kidney Function
This is an open-label study that will measure blood levels of different parts of a drug called GKS189075. People participating in this study will receive a single dose of 250mg GSK189075 by mouth.
- Conditions
- Type 2 Diabetes Mellitus, Diabetes Mellitus, Type 2, Renal Insufficiency
- Trial name
- NCT00501462
- Testing
- GSK189075
- Where
- 4 sites in United States
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma
Modified Immune Cells (Autologous CAR T Cells) in Treating Patients with Advanced, Recurrent Platinum Resistant Ovarian, Fallopian Tube or Primary Peritoneal Cancer
This is a Phase I/Ib dose escalation, dose expansion, study to evaluate the safety and identify the recommended dose of modified immune cells PRGN-3005 (autologous chimeric antigen receptor (CAR) T cells developed by Precigen…
- Conditions
- Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma, Platinum-Resistant Primary Peritoneal Carcinoma, Recurrent Fallopian Tube Carcinoma
- Trial name
- NCT03907527
- Testing
- PRGN-3005 UltraCAR-T cells
- Where
- 2 sites in United States
- Volunteers
- 71 people
- Sponsor
- Precigen, Inc
Renal Cell Carcinoma, Kidney Cancer
Trial of NanoDoce Intratumoral Injection in Renal Cell Carcinoma
This study evaluates the use of NanoDoce injected directly into tumors in the kidney of people with renal cell carcinoma.
- Conditions
- Renal Cell Carcinoma, Kidney Cancer, Adenocarcinoma of Kidney, Adenocarcinoma, Renal
- Trial name
- NCT04260360
- Testing
- NanoDoce (sterile nanoparticulate docetaxel) Powder for Suspension
- Sponsor
- NanOlogy, LLC
Chronic Kidney Disease
A Study of LY3113593 in Participants With Chronic Kidney Disease
This study is not intended to treat anemia of chronic kidney disease but to determine the safety of the study drug, LY3113593. The study will also evaluate how much of the study drug gets into the blood stream, how long it takes…
- Trial name
- NCT02604160
- Testing
- LY3113593
- Where
- 5 sites in United States
- Volunteers
- 7 people
- Sponsor
- Eli Lilly and Company
Prostate Cancer
Safety and Efficacy Study of Enzalutamide Versus Bicalutamide in Men With Prostate Cancer
The purpose of this study is to determine the safety and efficacy of enzalutamide vs bicalutamide in asymptomatic or mildly symptomatic patients with prostate cancer who have disease progression despite primary androgen…
- Trial name
- STRIVE (NCT01664923)
- Testing
- Enzalutamide, Bicalutamide
- Where
- 109 sites in United States
- Volunteers
- 396 people
- Sponsor
- Pfizer
Cancer, Breast Cancer
A Study Evaluating the Safety and Pharmacokinetics of ABBV-075 in Subjects With Cancer
This is a Phase 1, first-in-human, dose escalation study in participants with advanced solid tumors to determine the pharmacokinetics, maximum tolerated dose and the recommended Phase 2 dose of ABBV-075 at different monotherapy…
- Conditions
- Cancer, Breast Cancer, Non-Small Cell Lung Cancer, Acute Myeloid Leukemia (AML)
- Trial name
- NCT02391480
- Testing
- ABBV-075, Venetoclax
- Where
- 10 sites in United States
- Volunteers
- 128 people
- Sponsor
- AbbVie
Overactive Bladder, Neurogenic Detrusor Overactivity
Study Of Fesoterodine In Pediatric Overactive Bladder Patients Aged 8-17 Years
The purpose of the study is to evaluate the pharmacokinetics, safety, and tolerability of fesoterodine following administration to pediatric patients, aged 8-17 years, with overactive bladder.
- Trial name
- NCT00857896
- Testing
- Fesoterodine
- Where
- 9 sites in United States
- Volunteers
- 21 people
- Sponsor
- Pfizer
Ovarian Cancer
Clinical Trial of Lurbinectedin (PM01183) in Platinum Resistant Ovarian Cancer Patients
Multicenter, open-label, randomized, controlled phase III clinical trial to evaluate the activity and safety of PM01183 versus PLD or topotecan as control arm in patients with platinum-resistant ovarian cancer.
- Trial name
- CORAIL (NCT02421588)
- Testing
- Lurbinectedin (PM01183), Pegylated liposomal doxorubicin (PLD), Topotecan
- Where
- 28 sites in United States
- Volunteers
- 442 people
- Sponsor
- PharmaMar
Meningitis, Cryptococcal, HIV Infections
A Pilot Study of Fluconazole Plus Flucytosine for the Treatment of AIDS Patients With Acute Cryptococcal Meningitis.
To evaluate and estimate the safety and efficacy of the combination of fluconazole and flucytosine as treatment for acute cryptococcal meningitis in patients with AIDS.
- Trial name
- NCT00002113
- Testing
- Flucytosine, Fluconazole
- Where
- 3 sites in United States
- Volunteers
- 64 people
- Sponsor
- Pfizer
Cervical Cancer
A Clinical Study of Sacituzumab Tirumotecan (MK-2870) in Combination With Pembrolizumab (MK-3475) as First-line Maintenance Treatment of Cervical Cancer (MK-2870-036/TroFuse-036/GOG-3123/ENGOT-cx22)
Researchers are looking for new ways to treat metastatic cervical cancer. Cervical cancer is cancer in the cervix, the lower part of the uterus (womb). Metastatic means the cancer has spread to other parts of the body.
- Trial name
- NCT07216703
- Testing
- Pembrolizumab, Sacituzumab Tirumotecan, Bevacizumab
- Where
- 191 sites in United States, Argentina and 27 more
- Volunteers
- 1,023 people
- Sponsor
- Merck Sharp & Dohme LLC
Adenomyosis of Uterus, Implantation Failure
Linzagolix in Adenomyosis and Recurrent Implantation Failure
Adenomyosis is associated with impaired endometrial receptivity and reduced implantation rates in assisted reproduction, even when using high-quality embryos.
- Conditions
- Adenomyosis of Uterus, Implantation Failure, Infertility Female, Embryo Transfer
- Trial name
- LINZA-RIF (NCT07698561)
- Testing
- Linzagolix 200 mg (Yselty)
- Where
- 3 sites in Spain
- Volunteers
- 30 people
- Sponsor
- Vida Fertility Institute
HIV
Condom Performance in a Longitudinal Enhanced Assessment of User Experiences
This study will enroll 252 men who have sex with men (MSM) and 252 men who have sex with women (MSW) in a double-blind, three-way randomized crossover trial with conditions of fitted, thin, and standard condoms.
- Trial name
- C-PLEASURE (NCT02753842)
- Testing
- 5 Fitted Condoms, 5 Thin Condoms, 5 Standard Condoms
- Volunteers
- 504 people, healthy volunteers welcome
- Sponsor
- Global Protection Corp.
Ovarian Cancer, Breast Cancer
Prospective Multicentre Phase-IV Clinical Trial of Olaparib in Indian Patients With Ovarian and Metastatic Breast Cancer
A Prospective, Multicentre, Phase-IV Clinical Trial of Olaparib in Indian Patients with Platinum Sensitive Relapsed Ovarian Cancer who are in Complete or Partial Response Following Platinum based Chemotherapy and Metastatic…
- Trial name
- SOLI (NCT04330040)
- Testing
- Olaparib
- Where
- 16 sites in India
- Volunteers
- 202 people
- Sponsor
- AstraZeneca
Bladder Cancer
Exploring Engagement Dynamics Among Individuals Impacted by Bladder Cancer
The study seeks to delve into the firsthand experiences of patients diagnosed with bladder cancer who partake in a separate clinical trial featuring a specific medical intervention.
- Trial name
- NCT06009510
- Where
- United States
- Volunteers
- 500 people
- Sponsor
- Power Life Sciences Inc.
Prostatic Neoplasms
A Study to Learn About Novel Hormonal Therapies in People With Metastatic Castration-Sensitive Prostate Cancer (mCSPC)
The purpose of this study is to learn about how long novel hormonal therapies are taken by men to treat mCSPC. Novel hormonal therapies in this study include study medicines abiraterone, apalutamide, and enzalutamide.
- Trial name
- NCT06072196
- Testing
- Novel hormonal therapy
- Where
- United States
- Volunteers
- 3,017 people
- Sponsor
- Pfizer
Membranous Nephropathy
A Study to Assess Effectiveness and Safety of Efgartigimod in Chinese Patients with Primary Membranous Nephropathy (ZL-1103-014)
To evaluate the efficacy and safety of efgartigimod IV in Chinese patients with primary membranous nephropathy (pMN).
- Trial name
- NCT05810961
- Testing
- efgartigimod IV
- Where
- 31 sites in China
- Volunteers
- 8 people
- Sponsor
- argenx
Chronic Renal Failure, Chronic Kidney Disease
Safety and Efficacy of Peginesatide for the Treatment of Anemia in Participants With Chronic Renal Failure Not on Dialysis
The purpose of this study was to evaluate the safety and efficacy of peginesatide for the treatment of anemia in participants with chronic kidney disease, who are not on dialysis and not on erythropoiesis stimulating agent (ESA)…
- Conditions
- Chronic Renal Failure, Chronic Kidney Disease, Anemia
- Trial name
- PEARL 2 (NCT00598442)
- Testing
- peginesatide, Darbepoetin alfa
- Where
- 64 sites in United States, Bulgaria and 8 more
- Volunteers
- 493 people
- Sponsor
- Affymax
Autosomal Dominant Polycystic Kidney Disease
The ELiSA Study - Evaluation of Lixivaptan in Subjects With Autosomal Dominant Polycystic Kidney Disease
This is a Phase 2, open-label, parallel-group, multiple dose study designed to evaluate the pharmacokinetics, pharmacodynamics, safety and tolerability of multiple doses of lixivaptan in Autosomal Dominant Polycystic Kidney…
- Trial name
- NCT03487913
- Testing
- Lixivaptan
- Where
- 13 sites in United States
- Volunteers
- 31 people
- Sponsor
- Palladio Biosciences
Erectile Dysfunction
A Study to Evaluate the Safety and Effectiveness of Mirodenafil in Korean Patients With Erectile Dysfunction
The purpose of this study is to evaluate the safety and effectiveness of mirodenafil in participants with erectile dysfunction.
- Trial name
- NCT01802359
- Testing
- No intervention
- Volunteers
- 379 people
- Sponsor
- Janssen Korea, Ltd., Korea
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.